**Study on Alpha Radiation Emitters Device (DaRT) for Pancreatic Cancer** This study aims to treat advanced pancreatic cancer using a special method called DaRT, which stands for *Diffusing Alpha Radiation Therapy*. It involves placing small tubes coated with a radioactive material called Ra-224 into the tumor. This study is a type of clinical trial where doctors are testing if this method can help make tumors easier to remove with surgery. **Key Points:** - The study lasts for 12 months, with regular check-ups every 2 months to see if the tumor can be surgically removed. - Patients will take a drug called Capecitabine for 2 months after the DaRT is inserted. - Participants must have previously gone through 8-12 cycles of a chemotherapy treatment called mFOLFIRINOX. **Eligibility:** To join, patients need to be 18 or older and have a type of pancreatic cancer that fits certain medical criteria. They should be in generally good health and willing to follow the study’s guidelines, including using contraception to prevent pregnancy during and after the study. Certain health conditions, past treatments, or other ongoing medical issues may prevent participation.